This large population-based cohort of US adults with diabetes provided solid real-world evidence for incident AF events associated with GLP-1RA compared with other therapies (DPP4i, SGLT2i, and other non-insulin glucose-lowering agents other than SGLT2i)
While much of the conversation around GLP-1s focuses on weight and metabolic health, many people wonder: how do these medications affect sleep
2,32,33 POTENTIAL FUTURE THERAPIES Given the elevated GLP-1 levels and robust insulin response to glucose observed in PGBH, blocking GLP-1 may provide clinical benefit
It is a lab-engineered peptide drug with chemical modifications that make it longer-acting and more drug-like compared to native incretin hormones
A central mechanism underlying this process involves the release of mitochondria-derived damage-associated molecular patterns (DAMPs), most notably mtDNA and mtROS [98]
Parameters observed in preclinical animal models including quantities used, exposure durations, and inter-dose intervals are not validated for application to human subjects and should not be extrapolated as such
